Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Biomarkers

Topic: Brain proteins, microglia and lab models

Plain-language summary

We focus on neuroinflammation in disorders associated with frontotemporal lobar degeneration (FTLD). ResultsMyo-inositol was elevated in the R IFG ({beta} = 0.20, t = 5.10, p = 8.8 x 10^-7) but not in the R OCC ({beta} = 0.05, t = 1.36, p = 0.18), in people with FTLD versus controls. In FTLD, myo-inositol in the R IFG was positively associated with a peripheral inflammatory profile characterised by IL-6, IL-1{beta}, GFAP, CSF2, CRP, and CCL22 ({beta} = 0.39, t = 5.12, p = 3.60 x 10^-6). R IFG myo-inositol was negatively associated with ACE-R performance in patients ({beta} = -44.59, t = -4.12, p = 0.00016). Elevated levels in disease-affected regions were associated with peripheral markers of inflammation (reflecting astrocytosis and microgliosis) and with cognitive impairment.

What this study adds

Evidence grade: Low

This study found that a brain chemical marker, myo-inositol, was elevated in a disease-affected brain region in people with frontotemporal lobar degeneration and was linked to inflammation markers and worse cognitive scores. It is research into measuring neuroinflammation, not a treatment or cure.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Tan, S. Y., Naessens, M., Jones, P. S., Todd, E. G., Williams, R. S., Rodgers, C. T., et al. (2026). Myo-inositol as a spectroscopic marker of neuroinflammation in frontotemporal lobar degeneration. medRxiv (preprint). https://doi.org/10.64898/2026.09.18.26363386

Vancouver

Tan SY, Naessens M, Jones PS, Todd EG, Williams RS, Rodgers CT, et al. Myo-inositol as a spectroscopic marker of neuroinflammation in frontotemporal lobar degeneration. medRxiv (preprint). 2026. doi:10.64898/2026.09.18.26363386.

BibTeX

@article{tan2026-e830449b,
  author  = {Tan, S. Y. and Naessens, M. and Jones, P. S. and Todd, E. G. and Williams, R. S. and Rodgers, C. T. and Hughes, L. E. and Shapiro and others},
  title   = {{Myo-inositol as a spectroscopic marker of neuroinflammation in frontotemporal lobar degeneration}},
  journal = {medRxiv (preprint)},
  year    = {2026},
  doi     = {10.64898/2026.09.18.26363386},
  url     = {https://doi.org/10.64898/2026.09.18.26363386}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This study found that a brain chemical marker, myo-inositol, was elevated in a disease-affected brain region in people with frontotemporal lobar degeneration and was linked to inflammation markers and worse cognitive scores. It is research into measuring neuroinflammation, not a treatment or cure.

Study details

How this study scored 16/100
How this study's score is builtJournal tier 2 of 10; Journal's citation record 0 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 4 of 10; How recent 5 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year left out, no data; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 4 of 4; Institution's track record 2 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 1 of 2; Free to read 2 of 2. 23 of the 94 points it could be judged on, which is 24 of 100. Raw total 24 of 100, shown as 16 because this is not a peer-reviewed research article.raw total 24 of 100capped at 16 — hatched points do not count

Preprint — not yet peer-reviewed. It scored 24 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on impact for its field and year, so that was left out: it earned 23 of the 94 points we could judge it on, which is 24 out of 100.

ComponentPointsWhy
Journal tier 2 / 10 Tier 4 — not a peer-reviewed journal (medRxiv (preprint))
Journal's citation record 0 / 4 Not a journal article, so the journal's record does not count
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 4 / 10 Preprint — not yet peer-reviewed. Hosted on a preprint server.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 2 year(s) since 2026
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author James Benedict Rowe: h-index 101 (OpenAlex, whole career)
Institution's track record 2 / 3 University College London: institution h-index 2,029 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 9 institution(s) in 3 countries
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 2 / 2 Free to read
Points 23 / 94 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 23 of the 94 points we could judge it on is 24 out of 100.
Total 24 / 100 Capped to 16 because this is not a peer-reviewed article.

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Biomarkers from nearby years

Also tagged “tdp-43”

1,150 studies in the library carry the topic tag “tdp-43”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,150 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →